Hamidreza Mohammadi | Neuropharmacology | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Hamidreza Mohammadi
Affiliation Mazandaran University of Medical science
Country Iran
Scopus ID 56962768300
Documents 1264
Citations 1370
h-index 24
Subject Area Neuropharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7053-6850

Hamidreza Mohammadi is affiliated with Mazandaran University of Medical science, Iran, and has contributed to the fields of neuropharmacology, toxicology, oxidative stress research, mitochondrial dysfunction, and nanoparticle-mediated therapeutic development. His research profile reflects interdisciplinary investigations associated with pharmacological toxicology, mitochondrial protection, neuroprotective strategies, and oxidative injury mechanisms in experimental models.[1] His academic contributions include studies related to paraquat-induced neurotoxicity, nanoparticle therapeutics, oxidative stress biomarkers, and toxicological evaluation methodologies that are relevant to modern pharmaceutical and biomedical sciences.[2]

Abstract

The Innovative Research Award recognition highlights the scientific activities and academic contributions of Hamidreza Mohammadi in pharmaceutical toxicology and neuropharmacological sciences. His investigations include oxidative stress modulation, mitochondrial dysfunction analysis, paraquat-induced toxicity, nanoparticle-assisted therapeutic systems, and pharmacological interventions associated with cellular injury mechanisms. Published studies demonstrate collaborative research focused on toxicological pathways, mitochondrial protection, neuroprotective therapies, and nanomedicine-based pharmaceutical applications.[2] These scholarly activities have contributed to the advancement of experimental toxicology and translational pharmaceutical sciences in both preclinical and applied biomedical contexts.

Keywords

Neuropharmacology, Toxicology, Oxidative Stress, Mitochondrial Dysfunction, Paraquat Toxicity, Nanomedicine, Pharmaceutical Sciences, Experimental Pharmacology, Toxicological Research, Therapeutic Nanoparticles.

Introduction

Modern pharmaceutical sciences increasingly emphasize translational research approaches that integrate neuropharmacology, toxicology, nanotechnology, and mitochondrial medicine. Within this scientific environment, Hamidreza Mohammadi has participated in research investigating toxicant-induced cellular injury, neuroprotective mechanisms, oxidative stress pathways, and nanoparticle-assisted drug delivery systems. Several of his studies examine the biological consequences of paraquat exposure, mitochondrial dysfunction, and pharmacological interventions that may reduce oxidative injury in experimental models.[3] These investigations contribute to broader pharmaceutical discussions concerning therapeutic safety, oxidative balance, neurotoxicity prevention, and innovative biomedical strategies.

Research Profile

Hamidreza Mohammadi is associated with Mazandaran University of Medical Sciences and maintains an active academic profile in neuropharmacology and toxicological sciences.[1] His publication record includes collaborative investigations involving mitochondrial protection, toxicant-induced oxidative stress, neuroprotective therapeutics, nanoparticle systems, and pharmacological interventions targeting cellular dysfunction. His Scopus profile reports a substantial scholarly output and citation presence that reflects ongoing scientific engagement in pharmaceutical and biomedical research fields.[1]

Research Contributions

The scientific contributions of Hamidreza Mohammadi include studies focused on paraquat-induced neurotoxicity, oxidative mitochondrial injury, toxicological risk mechanisms, and nanoparticle-assisted therapeutic systems. Research publications have explored mitochondrial oxidative damage, antiemetic neuroprotection, toxicological evaluation of chemicals, and pharmacological mitigation of oxidative injury.[2] Additional work has examined the application of quercetin-loaded nanoparticles, curcumin formulations, and magnesium-based nanocarriers in experimental toxicology models.[4] These contributions collectively support scientific understanding of toxicant-induced physiological disruption and therapeutic intervention strategies.

Publications

Selected publications associated with Hamidreza Mohammadi include research articles in journals related to toxicology, pharmaceutical sciences, oxidative stress biology, and neuropharmacology. His studies investigate paraquat toxicity, mitochondrial dysfunction, nanoparticle therapeutics, and toxicological pharmacology using experimental models and translational biomedical approaches.[2]

Research Impact

The research activities of Hamidreza Mohammadi demonstrate interdisciplinary relevance across pharmaceutical toxicology, neuropharmacology, nanomedicine, and mitochondrial biology. His scholarly output contributes to scientific understanding of oxidative stress-mediated toxicity and therapeutic mitigation strategies. Research findings associated with nanoparticle formulations, mitochondrial protection, and toxicological pharmacology may support future investigations into safer pharmaceutical interventions and experimental therapeutic systems.[5] Citation metrics and publication activity further indicate continued engagement with internationally indexed pharmaceutical research platforms.

Award Suitability

The Innovative Research Award category is aligned with scholarly activities involving emerging pharmaceutical methodologies, toxicological innovation, and interdisciplinary biomedical research. Hamidreza Mohammadi’s work in oxidative stress mechanisms, neuroprotective pharmacology, toxicological assessment, and nanoparticle-based therapeutics reflects research themes commonly associated with contemporary pharmaceutical innovation.[3] His contributions demonstrate relevance to translational pharmaceutical sciences and experimental therapeutic development within academic and biomedical research communities.

Conclusion

Hamidreza Mohammadi has contributed to pharmaceutical and biomedical sciences through research activities centered on neuropharmacology, toxicology, oxidative stress, mitochondrial dysfunction, and nanomedicine. His publication profile reflects continued academic engagement in experimental toxicology and therapeutic investigation. The Innovative Research Award recognition acknowledges these scholarly contributions and their relevance to advancing pharmaceutical research methodologies and translational biomedical understanding.

References

  1. Elsevier. (n.d.). Scopus author details: Hamidreza Mohammadi, Author ID 56962768300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56962768300
  2. Jahani, R., Pourbahram, P., Seyedabadi, M., Nasiri, F., & Mohammadi, H. (2025). The role of GABAergic receptors in acute, subacute, and withdrawal syndrome on pain and seizure thresholds in mice: A connection to mitochondrial function and oxidative stress in the brain. Toxicology Reports.DOI: https://pubmed.ncbi.nlm.nih.gov/41312119/
  3. Sadeghi, S., Karami, M., Madanchi, H., Yazdian-Robati, R., Seyedabadi, M., Ghasempouri, S. K., Siahposht-Khachaki, A., & Mohammadi, H. (2025). Microfluidic techniques in the development of PLGA nanoparticles: a tri-combination therapy for paraquat-induced cytotoxicity. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfaf133
  4. Khederzadeh, A., Ebrahimnejad, P., Seyedabadi, M., Babaei, A., Talebpour Amiri, F., Aslani, N., Mojarad-Jabali, S., & Mohammadi, H. (2024). Synergistic effect of curcumin and Piperine loaded Niosomal nanoparticles on acute pulmonary toxicity induced by Paraquat in mice. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfae181
  5. Ashari, S., Karami, M., Shokrzadeh, M., Bagheri, A., Ghandadi, M., Ranaee, M., Dashti, A., & Mohammadi, H. (2022). Quercetin ameliorates Di (2-ethylhexyl) phthalate-induced nephrotoxicity by inhibiting NF-κB signaling pathway. Toxicology Research.DOI: https://doi.org/10.1093/toxres/tfac006

Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea — Ovidius University of Constanța
Mihaela Minea
Affiliation Ovidius University of Constanța
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of Constanța, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Ain Raal | Herbal Medicine and Nutraceuticals | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Ain Raal, University of Tartu, Estonia

Ain Raal
Affiliation University of Tartu
Country Estonia
Scopus ID 6505977002
Documents 2600
Citations 3199
h-index 30
Subject Area Herbal Medicine and Nutraceuticals
Event International Top Pharmaceutical Awards
ORCID 0000-0001-8731-7366

Ain Raal is associated with the University of Tartu in Estonia and is recognized for contributions to the field of herbal medicine, pharmacognosy, and nutraceutical sciences. His scholarly activities have focused on medicinal plants, natural products research, phytotherapy, and evidence-based applications of traditional remedies in pharmaceutical sciences.[1] The academic profile demonstrates extensive publication activity, interdisciplinary collaboration, and continued engagement with pharmaceutical and botanical research communities.[2]

Abstract

This article presents a scholarly overview of Ain Raal and his academic association with the University of Tartu. The profile highlights contributions to herbal medicine, medicinal plant research, nutraceutical sciences, and pharmaceutical education. Research activities include phytochemical evaluation, traditional medicine documentation, and evidence-based applications of natural products within pharmaceutical practice.[2] The article further summarizes publication activity, research influence, and academic relevance within contemporary pharmaceutical and botanical sciences.[3]

Keywords

Herbal Medicine, Nutraceuticals, Pharmacognosy, Medicinal Plants, Phytotherapy, Natural Products, Pharmaceutical Sciences, Traditional Medicine, University of Tartu, Estonia

Introduction

The study of herbal medicine and nutraceutical sciences has gained increasing importance within modern pharmaceutical research due to growing interest in evidence-based natural therapeutics and preventive healthcare strategies. Ain Raal has contributed to these fields through academic research, scientific publications, and participation in pharmaceutical education initiatives related to medicinal plants and pharmacognosy.[1] His association with the University of Tartu reflects engagement with interdisciplinary pharmaceutical sciences, including botanical medicine, phytochemistry, and natural product analysis.[4]

Research Profile

The academic profile of Ain Raal demonstrates sustained involvement in medicinal plant investigations and pharmaceutical sciences. His research interests include herbal therapeutics, traditional medicine validation, plant-derived bioactive compounds, and nutraceutical applications.[2] The documented publication record and citation metrics indicate long-term scholarly participation and recognition within pharmacognosy-related research communities.[1]

  • Research emphasis on herbal medicine and medicinal plants.
  • Academic involvement in nutraceutical and pharmaceutical sciences.
  • Contribution to evidence-based phytotherapy studies.
  • Participation in interdisciplinary scientific collaborations.

Research Contributions

Ain Raal has contributed to the scientific understanding of medicinal plants, phytotherapeutic compounds, and natural product applications in healthcare systems. Research contributions are associated with the documentation of traditional medicinal knowledge and the scientific assessment of herbal preparations.[3] These activities support broader pharmaceutical efforts aimed at integrating botanical resources into evidence-based healthcare frameworks.[5]

The publication activity also reflects engagement with pharmacognostic evaluation, herbal formulation studies, and natural product pharmacology. Such contributions are relevant to pharmaceutical innovation, nutraceutical product development, and public health research involving plant-derived therapeutics.[4]

Publications

Selected scholarly publications and indexed academic outputs associated with herbal medicine and pharmacognosy-related research include the following representative works.[2]

  • Research on medicinal plant applications in pharmaceutical sciences and herbal therapeutics.
  • Scientific investigations involving phytochemical and pharmacognostic evaluation of natural products.
  • Studies related to nutraceutical compounds and evidence-based herbal medicine.
  • Collaborative academic contributions within pharmaceutical and botanical research disciplines.

Research Impact

The research impact associated with Ain Raal is reflected through publication indexing, citation activity, and continuing scholarly relevance in herbal medicine and pharmaceutical sciences. Citation metrics and publication output indicate engagement with international research audiences and contribution to academic discourse related to medicinal plants and nutraceutical sciences.[1]

The h-index value and documented scholarly activity demonstrate sustained scientific productivity and influence within pharmacognosy-oriented literature. These metrics also indicate ongoing relevance in research areas connected to traditional medicine and natural product pharmacology.[5]

Award Suitability

The academic profile of Ain Raal aligns with recognition categories related to pharmaceutical sciences, herbal medicine, and nutraceutical research. The documented publication record, citation indicators, and sustained contributions to medicinal plant research demonstrate suitability for scholarly recognition within international pharmaceutical award platforms.[2]

The association with interdisciplinary pharmaceutical research and evidence-based herbal medicine further supports relevance to academic and professional recognition initiatives involving natural products and pharmacognosy research.[4]

Conclusion

Ain Raal represents an academic profile associated with sustained research activity in herbal medicine, medicinal plants, and nutraceutical sciences. The scholarly contributions, publication activity, and interdisciplinary pharmaceutical research engagement demonstrate continuing relevance within evidence-based natural product research. The documented academic indicators support recognition within pharmaceutical and pharmacognosy-related scientific communities.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ain Raal, Author ID 6505977002. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6505977002
  2. Raal, A. et al. (2019). Antihyperuricemic and xanthine oxidase inhibitory activities of Tribulus arabicus and its isolated compound, ursolic acid. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0202572
  3. Raal, A. et al. (2017). Therapeutic potentials of Crataegus azarolus var. eu-azarolus Maire leaves and its isolated compounds. BMC Complementary and Alternative Medicine.
    DOI: https://doi.org/10.1186/s12906-017-1729-9
  4. Raal, A. et al. (2020). Micromeria fruticosa induces cell cycle arrest and apoptosis in breast and colorectal cancer cells. Pharmaceuticals.
    DOI: https://doi.org/10.3390/ph13060115
  5. Raal, A. et al. (2022). Metabolic and biotransformation effects on dietary glucosinolates, their bioavailability, catabolism and biological effects in different organisms. Biotechnology Advances.
    DOI: https://www.sciencedirect.com/science/article/abs/pii/S0734975021000902

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. Martín Gimenez, V. M., García Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

David Suran | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

David Suran — Maribor University Medical Centre

David Suran
Affiliation Maribor University Medical Centre
Country Slovenia
Scopus ID 26650243300
Documents 310
Citations 332
h-index 11
Subject Area Cardiovascular Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-4073-9286

David Suran is a Slovenian clinician-scientist associated with Maribor University Medical Centre whose academic contributions focus on cardiovascular pharmacology, myocardial infarction research, renal complications in cardiovascular disease, and clinical cardiology. His published works demonstrate interdisciplinary engagement in cardiology, nephrology, internal medicine, and evidence-based cardiovascular outcomes research. Through extensive clinical investigations and collaborative medical publications, Suran has contributed to the understanding of myocardial infarction management, acute kidney injury, atrial fibrillation, cardiovascular risk assessment, and translational clinical medicine.[1]

Abstract

This academic article presents a structured overview of the research profile and scholarly contributions of David Suran in the fields of cardiovascular medicine and cardiovascular pharmacology. The article summarizes publication trends, citation indicators, collaborative clinical investigations, and thematic areas of research related to myocardial infarction, atrial fibrillation, acute kidney injury, cardiovascular outcomes, and evidence-based medicine. It further evaluates the suitability of the researcher for recognition under the Best Researcher Award category associated with the International Top Pharmaceutical Awards. The analysis reflects the researcher’s sustained participation in peer-reviewed scientific communication and clinically oriented medical investigations.[2]

Keywords

Cardiovascular Pharmacology, Myocardial Infarction, Acute Kidney Injury, Clinical Cardiology, Cardiovascular Outcomes, Internal Medicine, Atrial Fibrillation, Evidence-Based Medicine, Translational Medicine, Cardiovascular Research

Introduction

Cardiovascular diseases remain among the leading causes of global morbidity and mortality, thereby necessitating continuous scientific advancements in prevention, diagnosis, and therapeutic intervention. Clinical cardiology research plays a significant role in improving patient outcomes through observational studies, pharmacological assessments, and evidence-driven treatment approaches. David Suran has contributed to this research landscape through publications addressing cardiovascular complications, myocardial infarction management, renal impairment in cardiovascular conditions, and clinical predictors associated with adverse cardiovascular outcomes.[3]

His academic and clinical work demonstrates integration between hospital-based medical practice and scholarly research activities. Publications indexed through Scopus and ORCID indicate active participation in collaborative research initiatives involving cardiovascular medicine, nephrology, metabolic disorders, and public health-related cardiovascular investigations.[4]

Research Profile

David Suran is affiliated with Maribor University Medical Centre in Slovenia and serves in academic and clinical capacities associated with cardiology and cardiovascular medicine. ORCID records indicate involvement in internal medicine specialization, cardiovascular medicine specialization, and biomedical technology research training.[5]

The researcher’s Scopus profile records 310 documents, 332 citations, and an h-index of 11, reflecting sustained scholarly activity in cardiovascular medicine and related interdisciplinary areas. His research portfolio demonstrates thematic continuity in myocardial infarction studies, atrial fibrillation management, renal dysfunction following cardiovascular intervention, and prognostic cardiovascular biomarkers.[1]

  • Clinical specialization in cardiology and cardiovascular medicine
  • Research emphasis on myocardial infarction and cardiovascular complications
  • Peer-reviewed contributions to nephrology and cardiovascular outcomes research
  • Participation in collaborative translational medicine studies
  • Integration of evidence-based medicine within clinical cardiology practice

Research Contributions

A significant portion of Suran’s research has focused on cardiovascular risk assessment and patient outcomes in myocardial infarction populations. Publications investigating lipoprotein(a), acute kidney injury, obesity-related cardiovascular complications, and atrial fibrillation recurrence contribute to contemporary cardiovascular clinical understanding.[6]

Several studies have explored relationships between cardiovascular biomarkers and patient prognosis in acute myocardial infarction. Research addressing anemia, renal deterioration after percutaneous coronary intervention, and inflammatory or metabolic risk factors illustrates the clinical relevance of his investigations in routine medical practice.[3]

Additional investigations involving machine learning applications in medicine and explainable artificial intelligence demonstrate interdisciplinary engagement beyond traditional cardiovascular pharmacology. These contributions indicate evolving participation in digital health analytics and data-driven clinical methodologies.[3]

Publications

David Suran’s publications focus on cardiovascular pharmacology, myocardial infarction outcomes, atrial fibrillation, and renal complications associated with cardiovascular disease. His research includes clinical studies on lipoprotein(a), acute kidney injury, cardiovascular risk prediction, and interventional cardiology methodologies. Several works also examine evidence-based therapeutic approaches and translational medical applications in cardiovascular medicine.[4]

Research Impact

The scholarly contributions of David Suran demonstrate measurable academic engagement through peer-reviewed publications, interdisciplinary collaboration, and citation visibility in cardiovascular medicine. His work contributes to ongoing clinical discussions concerning myocardial infarction prognosis, cardiovascular complications, and evidence-based therapeutic approaches.[3]

Research outputs indexed in Scopus and ORCID further indicate continuity of scientific productivity and participation in internationally accessible medical literature databases. Studies involving cardiovascular risk biomarkers, renal complications, and outcome-based analyses hold practical significance for clinical cardiology and cardiovascular pharmacology research communities.[4]

Award Suitability

The Best Researcher Award recognizes individuals demonstrating sustained academic productivity, research quality, interdisciplinary collaboration, and meaningful scholarly contributions within their respective domains. David Suran’s publication profile, clinical research involvement, and documented scientific outputs indicate alignment with the evaluative expectations associated with international academic recognition programs.[4]

His research contributions to cardiovascular pharmacology and clinical cardiology demonstrate consistency in peer-reviewed dissemination, evidence-oriented investigation, and participation in clinically relevant scientific studies. The integration of cardiovascular outcomes research with practical clinical observations further strengthens the academic significance of his work within pharmaceutical and medical research communities.[4]

Conclusion

David Suran has established a research profile centered on cardiovascular medicine, myocardial infarction outcomes, and translational clinical investigations. His scholarly work reflects contributions to evidence-based cardiovascular research, interdisciplinary medical collaboration, and clinically applicable scientific inquiry. Through publications indexed in internationally recognized databases, Suran continues to contribute to the advancement of cardiovascular pharmacology and related medical sciences. The cumulative body of work supports his recognition within professional academic award frameworks focused on research excellence and clinical impact.[4]

References

  1. Elsevier. (n.d.). Scopus author details: David Suran, Author ID 26650243300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26650243300
  2. ORCID. (n.d.). David Suran ORCID profile and publication summary.https://orcid.org/0000-0002-4073-9286
  3. Suran, D. et al. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality. Diagnostics.https://doi.org/10.3390/diagnostics14232757
  4. Suran, D. et al. (2023). Obesity and Acute Kidney Injury in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine.https://doi.org/10.3390/jcm12237311
  5. ORCID. (n.d.). Professional activities and academic qualifications of David Suran.https://orcid.org/0000-0002-4073-9286
  6. Suran, D. et al. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Frontiers in Public Health.https://doi.org/10.3389/fpubh.2022.923797
  7. Suran, D. et al. (2019). Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention. Cardiorenal Medicine.https://doi.org/10.1159/000492287

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294